Paper33544313
Regression of portal hypertension: underlying mechanisms and therapeutic strategies.
Selicean S and 5 others. Hepatol Int, 2021. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Papers, record 33544313. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33544313
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypertension, Portal | Major topic |
| Esophageal and Gastric Varices | |
| Gastrointestinal Hemorrhage | |
| Humans | |
| Liver Cirrhosis | |
| Microcirculation |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06097715 | Clinical,Endoscopic and Radiological Assessment of Portal Hypertension in Children With Chronic Liver Diseases | Background |
Source ClinicalTrials.gov
References132
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28734831 | Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. | Gastroenterology | 2017 | https://conductscience.org/library/papers/28734831 | PubMed |
| 2 | 22032637 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. | Aliment Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22032637 | PubMed |
| 3 | 23216382 | Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. | J Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23216382 | PubMed |
| 4 | 27634134 | Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. | Liver Int | 2016 | https://conductscience.org/library/papers/27634134 | PubMed |
| 5 | 19157625 | Angiogenesis in liver disease. | J Hepatol | 2009 | https://conductscience.org/library/papers/19157625 | PubMed |
| 6 | 33128017 | Molecular and cellular mechanisms of liver fibrosis and its regression. | Nat Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33128017 | PubMed |
| 7 | 12500206 | Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. | Hepatology | 2003 | https://conductscience.org/library/papers/12500206 | PubMed |
| 8 | 28960366 | Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. | Hepatology | 2018 | https://conductscience.org/library/papers/28960366 | PubMed |
| 9 | 22365955 | Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. | Life Sci | 2012 | https://conductscience.org/library/papers/22365955 | PubMed |
| 10 | 20800926 | Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? | J Hepatol | 2010 | https://conductscience.org/library/papers/20800926 | PubMed |
| 11 | 32164767 | A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). | Trials | 2020 | https://conductscience.org/library/papers/32164767 | PubMed |
| 12 | 32535060 | Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. | J Hepatol | 2020 | https://conductscience.org/library/papers/32535060 | PubMed |
| 13 | 30765123 | Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. | Lancet | 2019 | https://conductscience.org/library/papers/30765123 | PubMed |
| 14 | 27941216 | Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling. | Aging (Albany NY) | 2016 | https://conductscience.org/library/papers/27941216 | PubMed |
| 15 | 16393289 | Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. | Aliment Pharmacol Ther | 2006 | https://conductscience.org/library/papers/16393289 | PubMed |
| 16 | 29922768 | Liver stiffness better predicts portal hypertension after HCV eradication. | J Gastrointestin Liver Dis | 2018 | https://conductscience.org/library/papers/29922768 | PubMed |
| 17 | 24764791 | Reversibility of liver fibrosis. | Gastroenterol Hepatol (N Y) | 2013 | https://conductscience.org/library/papers/24764791 | PubMed |
| 18 | 22271347 | A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. | Hepatology | 2012 | https://conductscience.org/library/papers/22271347 | PubMed |
| 19 | 23601333 | Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. | Liver Int | 2013 | https://conductscience.org/library/papers/23601333 | PubMed |
| 20 | 12475903 | Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. | FASEB J | 2003 | https://conductscience.org/library/papers/12475903 | PubMed |
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42753189 | Cirrhosis Impairs Reconstitution of the Circulating T-Lymphocyte Compartment After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. | United European Gastroenterol J | 2026 | https://conductscience.org/library/papers/42753189 | PubMed |
| 42519788 | Imaging-based fibrosis assessment and risk stratification in MASLD. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42519788 | PubMed |
| 42416937 | Diagnostic Accuracy of Liver and Spleen Elastography for Detecting Portal Hypertension Defined by Hepatic Venous Pressure Gradient (HVPG) in Chronic Liver Disease: A Systematic Review. | Cureus | 2026 | https://conductscience.org/library/papers/42416937 | PubMed |
| 41921416 | Single-cell fixed RNA profiling uncovers SEMA4D and LMCD1 as therapeutic targets in a liver fibrosis model. | JHEP Rep | 2026 | https://conductscience.org/library/papers/41921416 | PubMed |
| 41897531 | Cytoglobin in Hepatic Stellate Cells Plays Anti-Fibrotic Role in Chronic Liver Injury. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41897531 | PubMed |
| 41811796 | Recompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges. | Can J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41811796 | PubMed |
| 41669926 | Indocyanine Green Retention Rate at 15 Minutes as a Key Predictor of Clinically Significant Portal Hypertension in Cirrhosis: Development and Validation of a Superior Non-Invasive Diagnostic Model. | Turk J Gastroenterol | 2025 | https://conductscience.org/library/papers/41669926 | PubMed |
| 41659769 | Carvedilol decreases hepatic vascular resistance by reducing fibrogenesis and reversing endothelial dysfunction in cirrhotic rats. | JHEP Rep | 2026 | https://conductscience.org/library/papers/41659769 | PubMed |
| 41594255 | Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/41594255 | PubMed |
| 41368107 | Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study. | World J Hepatol | 2025 | https://conductscience.org/library/papers/41368107 | PubMed |
| 41024757 | Advances in portal hypertension management: Evolution of the Baveno guidelines. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/41024757 | PubMed |
| 40980160 | GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH. | JHEP Rep | 2025 | https://conductscience.org/library/papers/40980160 | PubMed |
| 40061591 | Multicenter analysis on the correlation between the anatomical characteristics of hepatic veins and hepatic venous wedge pressure. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/40061591 | PubMed |
| 39997697 | From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension. | Metabolites | 2025 | https://conductscience.org/library/papers/39997697 | PubMed |
| 39870944 | Preventing the progression of cirrhosis to decompensation and death. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39870944 | PubMed |
| 39732832 | Hemodynamic comparisons of different shunt positions and geometrical model simplification strategies in the simulation of transjugular intrahepatic portosystemic shunt (TIPS). | Sci Rep | 2024 | https://conductscience.org/library/papers/39732832 | PubMed |
| 39640222 | Mechanisms and implications of recompensation in cirrhosis. | JHEP Rep | 2024 | https://conductscience.org/library/papers/39640222 | PubMed |
| 39282182 | From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?). | Indian J Microbiol | 2024 | https://conductscience.org/library/papers/39282182 | PubMed |
| 38934697 | Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit. | Hepatol Commun | 2024 | https://conductscience.org/library/papers/38934697 | PubMed |
| 37842727 | Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease. | Gut Liver | 2024 | https://conductscience.org/library/papers/37842727 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33544313
GET https://conductscience.org/api/papers/v1/33544313/references?page=2